What Strategies do Brand-Name Companies Use to Delay Generic Entry?
Brand-name companies often employ various strategies to delay the entry of generic competitors. Patent evergreening involves making minor modifications to the original drug to extend its patent life. Another common tactic is pay-for-delay agreements, where brand-name companies pay generic manufacturers to postpone the release of their generic versions. Litigation is also a common method to delay generic competition.
